[Previous][Table of Contents][Next]
Only confirmed cases of disease should be notified.
Routine case-by-case notification to the federal level.
A confirmed case requires laboratory definitive evidence with clinical evidence or, in the case of foodborne botulism, clinical evidence and consumption of the same suspect food as an individual who has laboratory-confirmed botulism.
Laboratory confirmation of infection:
laboratory detection of botulinum toxin in
serum
OR
isolation of C. botulinum from a wound
AND
presence of a freshly infected wound in the 2
weeks before symptoms and no evidence of
consumption of food contaminated with
C. botulinum
Laboratory confirmation with symptoms
compatible with botulism in a person less than
one year of age:
detection of botulinum toxin in stool or serum
OR
isolation of C. botulinum from the patient’s
stool or at autopsy
Laboratory confirmation with symptoms
compatible with botulism in a patient aged
1 year or older with severely compromised
gastrointestinal tract functioning (i.e. abnormal
bowel) due to various diseases, such as
colitis, or intestinal bypass procedures, or in
association with other conditions that may
create local or widespread disruption in the
normal intestinal flora:
detection of botulinum toxin in stool or serum
OR
isolation of C. botulinum from the patient’s
stool or at autopsy
A probable case requires clinical evidence and consumption of a suspect food item in the incubation period (12-48 hours).
Any of the following will constitute a case of botulism:
Detection of botulinum toxin, with or without culture
Isolation of C. botulinum
Standard culture for C. botulinum with demonstration of neurotoxin
C. botulinum neurotoxin mouse bioassay
In wound and foodborne botulism C. botulinum neurotoxin may not be detectable in serum. Administration of antitoxin prior to withdrawal of blood will result in a negative assay.
While some strains of C. botulinum type C may not produce neurotoxin, two other species of the genus, C. baratii and C. butyricum may produce the neurotoxin.
Culture without toxin assay by mouse bioassay is not useful. Group I C. botulinum cannot be distinguished from C. sporogenes without toxin assay.
Isolates and/or clinical specimens should be referred to the National Botulism Reference Service or the British Columbia Centre for Disease Control
EIA for botulinum toxin is not as sensitive as the mouse bioassay and therefore should not replace the mouse bioassay for neurotoxin detection in clinical specimens; however, EIA could be used to detect neurotoxin production from cultures.
Foodborne: Clinical illness is characterized by blurred vision, dry mouth and difficulty swallowing and speaking. Descending and symmetric paralysis may progress rapidly, often requiring respiratory support.
Wound: Clinical illness is characterized by diplopia, blurred vision and bulbar weakness. Symmetric paralysis may progress rapidly.
Infant: Clinical illness in infants is characterized by constipation, loss of appetite, weakness, altered cry and loss of head control
Reportable to WHO under International Health Regulations
One case is considered an outbreak. Probable case definitions are provided as guidelines to assist with case finding and public health management, and are not for national notification purposes.
Protocol under development (Centre for Food-borne, Enteric and Zoonotic Infectious Diseases
CDC Notifiable Disease Case Definitions Taillac PP, Kim J. CBRNE-Botulism. Last updated June 2006. Available at:http://www.emedicine.com/emerg/topic64.htm
November 2008
[Previous][Table of Contents][Next]
To share this page just click on the social network icon of your choice.